Jiangsu Aidea Pharmaceutical Group Co., Ltd. (688488.SH) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenCNY 15.00

From 52W high−12.23%

Volume8.32M

Market capCNY 6.70B

P/E (TTM)−343.2x

P/S (TTM)9.2x

Div yield—

Key dataSep 18, 2026

Open

CNY 15.00

From 52W high

−12.23%

Volume

8.32M

Market cap

CNY 6.70B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

63.5x

P/E (TTM)

−343.2x

RSI (14)

48.6

MomentumView details →

1D Return

−3.40%

YTD Return

—

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

−343.2x

EV/EBITDA

63.5x

EV/Sales

9.6x

P/S (TTM)

9.2x

P/B (TTM)

6.9x

ProfitabilityView details →

Gross Margin

68.32%

Net Margin

−3.93%

EBITDA Margin

15.16%

ROE (TTM)

−2.82%

ROA (TTM)

−1.34%

Asset Turnover

0.35x

GrowthView details →

Revenue YoY

+33.77%

EPS YoY

+72.45%

FCF YoY

—

Revenue CAGR 3Y

+43.33%

EPS CAGR 3Y

+85.29%

EBITDA YoY

—

MomentumView details →

1D Return

−3.40%

YTD Return

—

1Y Return

—

RSI (14)

48.6

vs 50D SMA

−2.98%

vs 200D SMA

—

Capital & dividendView details →

Debt/Equity

0.68x

Current Ratio

1.50x

Quick Ratio

1.12x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

CNY 0.00

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

699.33M

Net Income (TTM)

−27.51M

Op. CF (TTM)

−21.23M

Latest newsMore news →

Aidea Pharmaceutical's board approved a 2026 plan to issue A-shares to specific investors, raising no more than RMB 945 million for the global clinical development of novel HIV integrase inhibitors, an annual production project of 500 million anti-HIV solid dosage form drugs, and supplemental working capital.3d ago

Aide Pharmaceutical announced its first-half 2026 results with revenue of 366 million yuan, up 0.93% year-on-year, and net profit attributable to shareholders of 22.93 million yuan, up 149.53% year-on-year.23d ago

Similar companies

Rhythm Pharmaceuticals, Inc.RYTM Arcellx, Inc.ACLX XD昊海生688366.SH CG Oncology, Inc. Common stockCGON 奥翔药业603229.SH Belite Bio, IncBLTE Find similar companies →

Latest newsMore news →

Aidea Pharmaceutical's board approved a 2026 plan to issue A-shares to specific investors, raising no more than RMB 945 million for the global clinical development of novel HIV integrase inhibitors, an annual production project of 500 million anti-HIV solid dosage form drugs, and supplemental working capital.3d ago Aide Pharmaceutical announced its first-half 2026 results with revenue of 366 million yuan, up 0.93% year-on-year, and net profit attributable to shareholders of 22.93 million yuan, up 149.53% year-on-year.23d ago